Makoto Kudo

2.1k total citations
61 papers, 1.2k citations indexed

About

Makoto Kudo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Makoto Kudo has authored 61 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 19 papers in Oncology and 19 papers in Epidemiology. Recurrent topics in Makoto Kudo's work include Tuberculosis Research and Epidemiology (9 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Makoto Kudo is often cited by papers focused on Tuberculosis Research and Epidemiology (9 papers), Lung Cancer Research Studies (9 papers) and Lung Cancer Treatments and Mutations (8 papers). Makoto Kudo collaborates with scholars based in Japan, United States and China. Makoto Kudo's co-authors include Dean Sheppard, Takeshi Kaneko, Xiaozhu Huang, Kamran Atabai, Katherine Huang, Yanli Wang, Chun Chen, John T. Li, Andrew C. Melton and Mary B. Engler and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Makoto Kudo

58 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Makoto Kudo Japan 15 365 323 318 281 238 61 1.2k
Fernando Botelho Canada 22 293 0.8× 525 1.6× 316 1.0× 298 1.1× 248 1.0× 34 1.3k
Quan Sha United States 16 453 1.2× 666 2.1× 194 0.6× 320 1.1× 222 0.9× 30 1.5k
Yoshiki Shiraishi Japan 21 450 1.2× 423 1.3× 528 1.7× 234 0.8× 73 0.3× 57 1.4k
Christof J. Majoor Netherlands 18 356 1.0× 142 0.4× 586 1.8× 229 0.8× 136 0.6× 50 1.3k
Masakazu Okamoto United States 20 272 0.7× 469 1.5× 208 0.7× 137 0.5× 114 0.5× 35 934
Edy Y. Kim United States 17 227 0.6× 761 2.4× 256 0.8× 304 1.1× 170 0.7× 40 1.5k
Denis Bedoret Belgium 11 197 0.5× 821 2.5× 202 0.6× 325 1.2× 254 1.1× 11 1.3k
Azzaq Belaaouaj France 14 165 0.5× 354 1.1× 281 0.9× 327 1.2× 130 0.5× 16 1.3k
Donghui Zhang China 20 175 0.5× 280 0.9× 179 0.6× 539 1.9× 143 0.6× 45 1.6k
Wendy Neveu United States 11 191 0.5× 393 1.2× 150 0.5× 253 0.9× 106 0.4× 14 957

Countries citing papers authored by Makoto Kudo

Since Specialization
Citations

This map shows the geographic impact of Makoto Kudo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Makoto Kudo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Makoto Kudo more than expected).

Fields of papers citing papers by Makoto Kudo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Makoto Kudo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Makoto Kudo. The network helps show where Makoto Kudo may publish in the future.

Co-authorship network of co-authors of Makoto Kudo

This figure shows the co-authorship network connecting the top 25 collaborators of Makoto Kudo. A scholar is included among the top collaborators of Makoto Kudo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Makoto Kudo. Makoto Kudo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kobayashi, Nobuaki, Hidetoshi Kawashima, Toshinori Tsukahara, et al.. (2023). Tailoring Therapeutic Strategies in Non-Small-Cell Lung Cancer: The Role of Genetic Mutations and Programmed Death Ligand-1 Expression in Survival Outcomes. Cancers. 15(21). 5248–5248. 5 indexed citations
2.
Yamamoto, Masaki, Ken Tashiro, Yu Hara, et al.. (2023). Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma. Thoracic Cancer. 14(25). 2601–2607. 2 indexed citations
3.
Kobayashi, Nobuaki, et al.. (2023). Thymic atypical carcinoid tumors with elevated mitotic counts in a patient with multiple endocrine neoplasia: A case report. Thoracic Cancer. 14(14). 1311–1315. 1 indexed citations
4.
Kobayashi, Nobuaki, et al.. (2023). Primary tracheal small‐cell carcinoma detected 11 months after surgery for pulmonary large‐cell neuroendocrine carcinoma: A case report. Thoracic Cancer. 14(13). 1212–1216. 1 indexed citations
5.
6.
7.
Hara, Yu, Ryo Nagasawa, Kota Murohashi, et al.. (2021). The Extent of Honeycombing on Computed Tomography Cannot Predict the Treatment Outcome of Patients with Acute Exacerbations of Interstitial Lung Disease. Canadian Respiratory Journal. 2021. 1–8. 1 indexed citations
8.
Hara, Yu, Kota Murohashi, Ryo Nagasawa, et al.. (2021). Comparison of Clinical Features between the High and Low Serum KL-6 Patients with Acute Exacerbation of Interstitial Lung Diseases. Canadian Respiratory Journal. 2021. 1–9. 4 indexed citations
9.
Kobayashi, Nobuaki, Keisuke Watanabe, Nobuyuki Horita, et al.. (2021). T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lung cancer. Thoracic Cancer. 12(11). 1726–1734. 5 indexed citations
10.
Kobayashi, Nobuaki, Keisuke Watanabe, Nobuyuki Horita, et al.. (2021). Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non‐small‐cell lung cancer: A multicenter retrospective trial. Thoracic Cancer. 13(2). 228–235. 11 indexed citations
11.
Watanabe, Keisuke, Yusuke Saigusa, Yu Hara, et al.. (2021). Effect of coexisting advanced extrapulmonary solid cancer on progression of Mycobacterium avium complex lung disease. Jornal Brasileiro de Pneumologia. 47(2). e20200520–e20200520. 1 indexed citations
12.
Kobayashi, Nobuaki, et al.. (2020). Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer. Thoracic Cancer. 11(4). 983–992. 5 indexed citations
13.
Kobayashi, Nobuaki, Hisashi Hashimoto, Kentaro Nakashima, et al.. (2020). Identification of a novel biomarker based on lymphocyte count, albumin level, and TBAg/PHA ratio for differentiation between active and latent tuberculosis infection in Japan. Tuberculosis. 125. 101992–101992. 12 indexed citations
14.
Kobayashi, Nobuaki, Hisashi Hashimoto, Kentaro Nakashima, et al.. (2020). MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer. Thoracic Cancer. 11(10). 2975–2982. 19 indexed citations
15.
Chen, Hao, Nobuyuki Horita, Kentaro Ito, et al.. (2020). Systematic review of first-line chemotherapy for chemo-naïve extensive-stage small-cell lung cancer: network meta-analysis. Therapeutic Advances in Medical Oncology. 12. 3863580881–3863580881. 7 indexed citations
16.
Kobayashi, Nobuaki, et al.. (2019). Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib. Respirology Case Reports. 7(7). e00453–e00453. 4 indexed citations
17.
Tashiro, Ken, Masaki Yamamoto, Ryota Ushio, et al.. (2019). Hepcidin exerts a negative immunological effect in pulmonary tuberculosis without HIV co-infection, prolonging the time to culture-negative. International Journal of Infectious Diseases. 86. 47–54. 5 indexed citations
18.
19.
Kobayashi, Nobuaki, et al.. (2019). Computed tomography imaging‐based observation of the aggressive growth of angiosarcoma: a case study. Respirology Case Reports. 7(8). e00479–e00479. 4 indexed citations
20.
Masuda, Makoto, Takashi Sato, Kentaro Sakamaki, et al.. (2015). The effectiveness of sputum pH analysis in the prediction of response to therapy in patients with pulmonary tuberculosis. PeerJ. 3. e1448–e1448. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fernando Botelho Breakdown of academic impact, for papers by Quan Sha Breakdown of academic impact, for papers by Yoshiki Shiraishi Breakdown of academic impact, for papers by Christof J. Majoor Breakdown of academic impact, for papers by Masakazu Okamoto Breakdown of academic impact, for papers by Edy Y. Kim Breakdown of academic impact, for papers by Denis Bedoret Breakdown of academic impact, for papers by Azzaq Belaaouaj Breakdown of academic impact, for papers by Donghui Zhang Breakdown of academic impact, for papers by Wendy Neveu
Rankless by CCL
2026